PCRX Pacira BioSciences Inc.

43.89
+0.07  (+0%)
Previous Close 43.82
Open 43.7
Price To Book 5.29
Market Cap 1,831,565,119
Shares 41,730,807
Volume 421,620
Short Ratio
Av. Daily Volume 517,177
Stock charts supplied by TradingView

NewsSee all news

  1. Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services

    PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician

  2. Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

    PARSIPPANY, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of

  3. Pacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    PARSIPPANY, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference at 9:30 AM PT (12:30 PM ET) on

  4. EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients

    PARSIPPANY, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean

  5. Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric Patients

    PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from its Phase 3 PLAY

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Approval announced April 6, 2018.
EXPAREL
Post surgical pain
sNDA due 1H 2020.
EXPAREL - pediatric patients
Postoperative Pain Management

Latest News

  1. Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services

    PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician

  2. Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

    PARSIPPANY, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of

  3. Pacira BioSciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    PARSIPPANY, N.J., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the 38th Annual J.P. Morgan Healthcare Conference at 9:30 AM PT (12:30 PM ET) on

  4. EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients

    PARSIPPANY, N.J., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) in patients undergoing Cesarean

  5. Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric Patients

    PARSIPPANY, N.J., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced positive results from its Phase 3 PLAY

  6. Pacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference

    PARSIPPANY, N.J., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the 31st Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3,

  7. Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference

    PARSIPPANY, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday,

  8. Pacira BioSciences Reports Third Quarter 2019 Financial Results and Business Update

    -- Total revenues increased 25 percent over prior year to $104.7 million in third quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.

  9. Pacira to Report Third Quarter 2019 Financial Results on Thursday November 7, 2019

    PARSIPPANY, N.J., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday,

  10. Pacira BioSciences Set to Join S&P SmallCap 600

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September 30. Apollo

  11. Pacira BioSciences Appoints Chris Christie to Board of Directors

    PARSIPPANY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J.

  12. Pacira BioSciences Completes Enrollment in Multicenter Registration Study of EXPAREL® in Pediatric Patients

    PARSIPPANY, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), a leading provider of innovative non-opioid pain management options, today announced that it has reached full enrollment of